Published in final edited form as:

Mol Cancer Ther. 2014 February ; 13(2): 475–482. doi:10.1158/1535-7163.MCT-13-0817.

Acquired resistance to dasatinib in lung cancer cell lines conferred by *DDR2* gatekeeper mutation and *NF1* loss

Ellen M. Beauchamp¹, Brittany A. Woods^{1,2}, Austin M. Dulak¹, Li Tan³, Chunxiao Xu¹, Nathanael S. Gray⁴, Adam J. Bass^{1,5}, Kwok-kin Wong^{1,6}, Matthew Meyerson^{1,5,7}, and Peter S. Hammerman^{1,5}

¹Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

²Graduate School of Biomedical Sciences, Memorial Sloan-Kettering Cancer Center, New York, New York

³Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston MA

⁴Department of Biological Chemistry and Molecular Pharmacology, Dana-Farber Cancer Institute, Boston, MA

⁵Broad Institute Cancer Program, Cambridge MA

⁶Belfer Institute of Applied Cancer Sciences, Boston, MA

⁷Department of Pathology, Brigham and Womens Hospital, Boston, MA

Abstract

The treatment of non-small cell lung cancer has evolved dramatically over the past decade with the adoption of widespread use of effective targeted therapies in patients with distinct molecular alterations. In lung squamous cell carcinoma (lung SqCC) recent studies have suggested that *DDR2* mutations are a biomarker for therapeutic response to dasatinib and clinical trials are underway testing this hypothesis. While targeted therapeutics are typically quite effective as initial therapy for patients with lung cancer, nearly all patients develop resistance with long-term exposure to targeted drugs. Here, we use *DDR2*-dependent lung cancer cell lines to model acquired resistance to dasatinib therapy. We perform targeted exome sequencing to identify two distinct mechanisms of acquired resistance: acquisition of the T654I gatekeeper mutation in *DDR2* and loss of *NF1*. We show that *NF1* loss activates a bypass pathway which confers *ERK* dependency downstream of *RAS* activation. These results indicate that acquired resistance to dasatinib can occur via both second-site mutations in *DDR2* and by activation of bypass pathways. These data may help to anticipate mechanisms of resistance which may be identified in upcoming clinical trials of anti-*DDR2* therapy in lung cancer and suggest strategies to overcome resistance.

Keywords

Squamous cell lung cancer; *DDR2* mutation; dasatinib; lung cancer genomics; acquired resistance

Correspondence to: Peter Hammerman MD, PhD, Dana-Farber Cancer Institute, 450 Brookline Ave, Dana 810A, Boston, MA 02215, 617-632-3000 (p), 617-582-7880 (f), phammerman@partners.org.

Potential Conflicts of Interest: M.M. is a founding advisor and consultant to, and an equity holder in, Foundation Medicine. P.S.H. reports consulting fees from ARIAD, ImClone, and Molecular MD.

Introduction

For patients with lung adenocarcinoma, the most common subtype of non-small cell lung cancer (NSCLC), genomic studies have identified several targetable molecular alterations. Alterations in *EGFR* (1–3) and *ALK* (4, 5), and more recently, *BRAF* (6, 7), *ROS1* (8, 9) and *RET* (10–12), have been associated with marked responses to small molecule kinase inhibitors in clinical trials and therapies targeting *EGFR* and *ALK* genomic alterations are FDA approved. These targeted therapies are both more efficacious and less toxic than standard chemotherapy in selected populations and have led to a paradigm shift in the management of lung adenocarcinoma.

Lung squamous cell carcinoma (lung SqCC) is the second most common subtype of NSCLC and is a lethal disease which is diagnosed in 40–50,000 patients per year in the United States (13). The majority of patients present with locally advanced or metastatic disease. Recent studies of lung SqCC have identified recurrent alterations in tyrosine kinases including amplifications, mutations and translocations of Fibroblast Growth Factor Receptors (FGFRs) (14–18) and mutations in the Discoidin Domain Receptor 2 gene (*DDR2*) (19, 20).

FGFR1 amplification and *DDR2* mutation have been associated with response to targeted agents in pre-clinical models and in early phase clinical trials (19, 21, 22). These studies have led to interest in the development of targeted therapeutic approaches specifically for lung SqCCs given that there are no targeted agents approved in this disease. Several ongoing clinical trials are investigating therapeutic biomarkers in lung SqCCs including *FGFR* mutations and amplifications as well as *BRAF*, *PIK3CA* and *DDR2* mutations (www.clinicaltrials.gov).

In lung adenocarcinoma the success of targeted therapies has been limited by the observation that nearly all treated patients develop acquired resistance to the targeted agent over time. Studies of lung cancer cell lines with sensitizing mutations and patient-derived re-biopsy specimens have demonstrated that acquired resistance can occur as a result of secondary mutations in the original target, such as *EGFR* T790M (23, 24) and *ALK* L1196M (25, 26), or by activation of parallel pathways which bypass the original target such as *MET* (27) or *ERBB2* amplification (28). Pre-clinical models of acquired resistance have been robust in predicting mechanisms of resistance identified in the clinic (29–35) and there are substantial efforts underway to identify strategies to overcome acquired resistance to targeted agents for multiple lung cancer genotypes. These issues are not limited to lung cancer as acquired resistance to targeted agents is an increasing problem across many cancer cell types, and multiple mechanisms of acquired resistance have been reported to date.

Dasatinib is an FDA-approved oral tyrosine kinase inhibitor which has been studied in several trials of lung cancer patients (36–38). While the response rate to dasatinib as a single agent has been low in general, several responders have been reported, including two individuals with *DDR2* S768R mutations (19, 22) and an individual with a *BRAF* mutation (39), suggesting that specific biomarkers may be predictive of response to dasatinib. An international clinical trial is now accruing patients with these genotypes to address the efficacy of dasatinib in genomically selected patient cohorts with advanced NSCLC (NCT01514864). There has been no study reported to date of mechanisms of acquired resistance to dasatinib in the lung cancer population.

DDR2 is a receptor tyrosine kinase which functions as a cellular collagen receptor (40, 41). Activation of *DDR2* has been associated with a number of cellular phenotypes including transformation, migration and differentiation (40, 42). *DDR2* mutations are present in 3–4% of patients with lung SqCC and have been reported in other cancer types at comparable

frequencies including lung adenocarcinoma, uterine cancer, stomach cancer, bladder cancer, melanoma, colorectal cancer and head and neck cancer (www.cbioportal.org). DDR2 engages a number of downstream signaling pathways including PI3K/AKT, Src, MEK/ERK and NF- κ B to drive cell survival, proliferation, migration and transformation (43–47). DDR2 is potently inhibited by several FDA approved tyrosine kinase inhibitors including dasatinib, nilotinib, imatinib and ponatinib (48). While all of these kinase inhibitors are active against *DDR2* mutated lung cancer cell lines dasatinib is the most potent *in vitro* and *in vivo*. The potency of dasatinib against DDR2 has led to the design of clinical trials testing its efficacy in lung cancer patients with *DDR2* mutations.

Here we report the generation of two cell line models of acquired resistance to dasatinib in *DDR2* mutated lung cancer cell lines (HCC-366 and NCI-H2286) which have been previously shown to be dasatinib-sensitive and *DDR2*-dependent (19). Targeted exome sequencing analysis of these lines demonstrated acquisition of a second-site mutation (T654I) in *DDR2* in HCC-366 as the only novel mutation as compared to the parental cell line. In contrast, three alterations were identified in NCI-H2286, none of which was a second-site mutation in *DDR2*. In NCI-H2286 loss of *NF1* was the most potent alteration associated with acquired resistance and activated a bypass pathway characterized by increased RAS and ERK activity.

Materials and Methods

Cell culture

Lung cancer cell lines (NCI-H2286, HCC-366 and NCI-H1703) were obtained from the ATCC and maintained in RPMI 1640 (Invitrogen) plus 10% Fetal Calf Serum (Gemini). Experiments were performed within six months of receipt of cell lines from ATCC and no further authentication was performed. Dasatinib was obtained from LC labs. NCI-H2286 and HCC-366 cells were grown in increasing concentrations of dasatinib beginning at 100 nM and increasing to 1.5 μ M over a period of three to four months.

DNA sequencing

Genomic DNA was prepared from HCC-366, NCI-H2286 and two independent clones of NCI-H2286-DR and HCC-366-DR using the Qiagen DNeasy Kit. DNA was quantified by Pico-Green (Invitrogen) and 200 ng used for solution based hybrid capture using the Oncopanel capture kit (49). This was followed by massively parallel sequencing on the Illumina Hiseq 2000. FASTQ files were aligned using the Picard pipeline and mutations called using Mutect and annotated using Oncotator using the parental cell line as the reference sequence (20). Analysis methods are also described at www.broadinstitute.org/cancer/cga.

Immunoblotting

Cellular lysates were prepared using RIPA buffer supplemented with protease and phosphatase inhibitors. Immunoblotting was performed using the Nupage system (Invitrogen) with 100 μ g of lysate. Primary antibodies used were: NF1 (Santa Cruz Biotechnology), DDR2 (Bethyl Laboratories), p-TYR clone 4G10 (Millipore), Erk (Cell Signaling Technologies), p-Erk1/2 (Thr202/Tyr204) (Cell Signaling Technologies), Src (Cell Signaling Technologies), p-Src (Tyr416) (Cell Signaling Technologies), Mek (Cell Signaling Technologies), p-Mek (Ser217/221) (Cell Signaling Technologies), Akt (Cell Signaling Technologies), p-Akt (Ser473) (Cell Signaling Technologies), β -actin (Sigma), and vinculin (Sigma). Immunoprecipitation was performed by incubating 2 mg of lysate with 10 μ L antibody for 1 hour at 4 degrees with shaking. 30 μ L of protein A agarose (Invitrogen) was then added, followed by a 2 hour incubation at 4 degrees with shaking. The

agarose was washed three times with RIPA buffer and resuspended in SDS sample buffer (Boston BioProducts). Immunoblotting was then performed using the Nupage system (Invitrogen).

RNAi

shRNA vectors targeting *NF1* were obtained from The RNAi Consortium at the Broad Institute. Hairpin shNF1a corresponds to TRC clone TRCN0000039714, shNF1b corresponds to clone TRCN0000039716, shNF1c corresponds to clone TRCN0000039715, and shNF1e corresponds to clone TRCN0000039713. All hairpins were provided in the PLKO.1 vector. Hairpins targeting GFP, LacZ29 or LacZ1650 were also obtained from TRC and used as controls. Lentivirus expressing the shRNAs was generated using a previously described triple transfection system with 293T cells as the packaging cell line. NCI-H2286, HCC-366 and NCI-H1703 were infected with a 1:8 titer of virus for 6 hours in the presence of 8 µg/ml polybrene. Cells were selected for stable expression of the shRNA construct by puromycin selection at 2 µg/mL for NCI-H2286 and 4 µg/mL for NCI-H1703 and HCC-366. Knock-down was confirmed by both real-time PCR and immunoblot. ERK1/2 knockdown was performed using siRNAs purchased from Cell Signaling Technologies (SignalSilence). Cells were transfected with a mixture of the siRNA and Lipofectamine 2000 (Invitrogen) and were assayed at 24, 48, and 72 hours.

RAS activity assay

The activation of RAS was detected using the Ras Activation Kit (Millipore, Billerica, MA) according to the manufacturer's instructions. In short, 300 µg of cell lysate was incubated with Raf1 Ras-binding domain conjugated to glutathione S-transferase for 30 minutes at 4°C. Precipitates were washed three times, resuspended in 2× Laemmli sample buffer, and resolved by SDS-polyacrylamide gel electrophoresis using 12% gels. Proteins were transferred to Immobilon-FL membranes and subjected to immunoblotting with the RAS10 antibody (Millipore).

Cell Proliferation and Viability Assays

Cell proliferation was measured with the Cell-Titer-Glo reagent (Promega) per the manufacturer's instructions. Cells were plated at a density of 1500 cells/well in clear-bottomed 96-well plates. Drug was added the following day and cell proliferation was measured 6 days later using a standard 96-well plate luminometer. Percent survival at a given drug concentration was determined by comparing the luminescence at that concentration to that of untreated cells of the same cell type. For the *ERK* knockdown experiment, cells were seeded at a density of 250,000 cells/plate in 60mm dishes. siRNA was added the following day, and cell viability was measured 24, 48, and 72 hours after addition of siRNA with a Vi-CELL reader, which stained cells with trypan blue and generated 50 independent images for each sample.

Results

Generation and analysis of dasatinib resistant cell lines

We cultured two cell lines, HCC-366 and NCI-H2286, previously shown to be *DDR2*-mutated, *DDR2*-dependent and dasatinib-sensitive (19) in increasing concentrations of dasatinib to generate resistant cell populations. The previously reported GI_{50} for these lines with dasatinib treatment is 140 nM and we increased dasatinib doses to a target of at least ten times the baseline GI_{50} . Two independent clones were generated for each cell line and calculated GI_{50} s for the resistant pooled lines were 15.4 µM for HCC-366-DR and 4.5 µM

for NCI-H2286-DR (Figure 1A). Levels of DDR2 protein did not change as a result of the acquisition of dasatinib resistance (Figure 1B).

To define mechanisms of resistance to dasatinib in these cell lines we extracted genomic DNA from resistant clones and parental lines. Targeted exome sequencing was performed using the previously described Oncopanel hybrid-capture system (49) followed by massively parallel sequencing using the Illumina Hiseq 2000. 645 genes were targeted and a mean sequencing depth of 320× was achieved across covered regions. Variant calling using Mutect (20) (www.broadinstitute.org/cancer/cga) to annotate variants present in the resistant and not parental lines identified only one variant in one of the HCC-366 dasatinib resistant lines (*DDR2* T654I), a mutation previously reported by our group and others (Table 1).

DDR2 T654I is a gatekeeper mutation site which confers dasatinib resistance in a manner analogous to *EGFR* T790M (50). We have shown previously that expression of *DDR2* T654I mutants in HCC-366 and NCI-H2286 confers dasatinib resistance, with an increase in GI_{50} of 209- and 35-fold respectively for dasatinib in HCC-366 and NCI-H2286 (19). While dasatinib treatment led to decreased phosphorylation of mutated *DDR2* in parental NCI-H2286 and HCC-366 cells, expression of the *DDR2* T654I acquired mutation blocked this effect (Supplemental Figure 1). Similarly, dasatinib treatment led to decreased phosphorylation of *DDR2* in NCI-H2286-DR but not HCC366-DR (Supplemental Figure 1). In NCI-H2286-DR clones, we did not identify any second-site mutations in *DDR2*, but we did identify variants including a splice-site mutation in *NF1* and missense mutation in *EPHA7* (V560L) in one clone and *IL6ST* (A664S) in a second clone (Table 1).

Functional assessment of mutations associated with acquired resistance

Given that the *DDR2* T654I has been extensively characterized in the past by our group, we did not pursue additional experiments to further characterize the gatekeeper mutation (19,49). Our observation that *DDR2* phosphorylation was maintained in HCC-366-DR with dasatinib suggests a similar gatekeeper mechanism in our study (Supplemental Figure 1).

We focused our analysis on the NCI-H2286 dasatinib-resistant clones by determining protein expression for the three genes identified by targeted sequencing (*IL6ST*, *EPHA7* and *NF1*). No difference in protein level was noted in *EPHA7* or *IL6ST* in the resistant clones as compared to the parental lines (data not shown), but we observed a decrease in *NF1* protein in the dasatinib-resistant clone harboring the *NF1* splice site mutation (Figure 2A-lane 2). Ectopic expression of *IL6ST* A664S in parental NCI-H2286 cells resulted in no effect on dasatinib sensitivity and was not pursued further (Supplemental Figure 2). Given recent reports that *EPHA7* is a tumor suppressor (51) we also evaluated whether knock-down of *EPHA7* might drive dasatinib resistance but this was not observed (Supplemental Figure 2).

In contrast, we screened four shRNAs to evaluate knock-down of *NF1* in NCI-H2286 by immunoblot and real-time PCR (Figures 2A and 2B). All four shRNA vectors decreased *NF1* mRNA and three of four had an appreciable effect on protein level (Figures 2A and 2B). We then assessed whether *NF1* knockdown in parental NCI-H2286 cells impacted the sensitivity to dasatinib and observed a decrease in dasatinib sensitivity using all of the shRNA vectors (Figure 2C). In an average of three independent experiments the GI_{50} was 65.9 nM for the parental line expressing control shRNA targeting the *lacZ* gene (shLACZ) and 1.9 μ M in the dasatinib resistant line. Parental NCI-H2286 cells expressing shRNA vectors targeting *NF1* displayed GI_{50} s ranging from 122 to 544 nM, a 1.85 to 8.3 fold shift in GI_{50} compared to the parental cell line expressing shLACZ.

Correlation of dasatinib resistance with maintained ERK activation

We next aimed to elucidate downstream signaling alterations in NCI-H2286-DR through comparison of effector molecule phosphorylation relative to parental NCI-H2286 by western blotting. DDR2 has been previously shown to engage the PI3K/AKT, Src and ERK/MAPK signaling cascades (43–47). Additionally, ERK1/2 activity is essential for DDR2-driven cellular migration and differentiation (40–42). While we did not observe any difference in the levels of p-AKT, p-MEK or p-Src when comparing the response of resistant and parental NCI-H2286 lines to dasatinib, we observed that p-ERK levels were maintained in dasatinib treated NCI-H2286-DR cells and not in the parental cell lines (Figure 3). Interestingly, both p-Src and p-MEK were decreased to a comparable fashion in parental NCI-H2286 cells and NCI-H2286-DR suggesting that effects of dasatinib on at least one of its cellular targets may be independent of the changes in signaling observed in the context of dasatinib resistance. To this effect, we observed no difference in sensitivity of NCI-H2286 and NCI-H2286-DR cells to the MEK inhibitor GSK1120212 (Supplemental Figure 3).

NF1 is a negative regulator of RAS activity. Given that we observed increased p-ERK1/2 in NCI-H2286-DR, we measured RAS activity by RAS GTPase assay. We observed RAS activity was elevated in NCI-H2286-DR as compared to NCI-H2286 by RAS GTPase assay (Figure 4A). Since we observed that ERK1/2 but not MEK phosphorylation was elevated in NCI-H2286-DR as compared to parental NCI-H2286 in the setting of dasatinib, we hypothesized that ERK1/2 may be required for cell viability or proliferation in the dasatinib resistant cells. Previous work has shown that ERK1/2 is the most critical effector of the MAPK pathway in the setting of resistance to vemurafenib in melanoma cell lines (52) with MEK activity less critical. To address whether analogous activation of ERK1/2 downstream of NF1-mediated RAS activation was required for the resistance phenotype we used RNAi to knock-down *ERK1/2* in NCI-H2286 and NCI-H2286-DR (Figure 4B). We observed that knock-down of *ERK1/2* led to a dramatic decrease in cell viability and proliferation in both the parental and dasatinib-resistant cell line (Figure 4B), suggesting that ongoing ERK1/2 activity is required in the setting of dasatinib resistance in NCI-H2286-DR as well as in the parental cell line. This may be due to the existence of a DDR2-ERK signaling axis in the parental line which is bypassed by a NF1-ERK axis in the resistant line; in both cases signaling through ERK is required for cell proliferation.

Generalizability of NF1 loss as a mechanism of acquired resistance to dasatinib

NF1 loss has been nominated as a mechanism of acquired resistance to both *BRAF* and *EGFR*-directed therapy (35). Activation of other signaling molecules in the RAS/RAF/MEK/ERK pathway has been described in the setting of acquired resistance to *BRAF* inhibitors (34). Given that *NF1* loss appeared to drive acquired resistance in the setting of NCI-H2286-DR, we also probed two additional dasatinib-sensitive lung cancer cell lines to examine if *NF1* loss may be a general mechanism of resistance to dasatinib in the lung cancer context.

We selected two cell lines for this analysis: HCC-366 which harbors the *DDR2* mutation L239R, and NCI-H1703 which has no *DDR2* mutations but is dasatinib-sensitive due to dependence on *PDGFRA* amplification (53). We knocked-down *NF1* in both lines using the shRNA construct in Figure 2 which led to the greatest degree of NF1 depletion (Figure 5A). We observed that *NF1* knock-down in both HCC-366 and NCI-H1703 led to a decrease in dasatinib sensitivity (Figure 5B). The calculated GI₅₀ shifts were 11.1-fold for NCI-H1703 (4.8 to 53.5 nM) and 3.0-fold for HCC-366 (10.6 to 32 nM) when comparing lines expressing the shRNA targeting *NF1* as compared to an shRNA targeting *GFP*.

Discussion

Here we have generated cellular models of acquired resistance to dasatinib using two independent *DDR2* mutated lung cancer cell lines, both previously shown to be sensitive to dasatinib at comparable concentrations. Targeted exome sequencing of resistant lines identified two different modes of acquired resistance to dasatinib, second site (gatekeeper) mutations in *DDR2* and loss of *NF1*. These results are analogous to the cases of *EGFR* and *ALK* resistance in lung cancer in which both cis events such as gatekeeper mutations as well as trans events involving activation of other genes and bypass pathways have been shown to drive acquired resistance to *EGFR*- or *ALK*-directed therapy.

The development of pharmaceutical agents to selectively target gatekeeper mutations has been successful in the case of *EGFR* T790M with compounds such as WZ-4002 and CO-1686 (54) and for BCR-ABL with second- and third-generation ABL inhibitors. Our data suggest that the development of *DDR2* inhibitors with activity against gatekeeper mutations is warranted given the likelihood that patients on clinical trials of dasatinib or other *DDR*-directed therapies will develop *DDR2* gatekeeper mutations associated with failure of initial therapy.

Loss of *NF1* has recently been reported to drive resistance to tyrosine kinase inhibitors in a number of settings including *BRAF*-driven melanoma and *EGFR*-driven lung cancer (35). *NF1* loss is also increasingly thought to play an important role in oncogenesis in a wide spectrum of tumor types and has been reported as a recurrently mutated gene by a number of cancer genome studies (<http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/>). Our data indicate another setting in which *NF1* loss contributes to tyrosine kinase inhibitor resistance and suggests that it can drive resistance to dasatinib in sensitive cell lines with different mechanisms of sensitivity to dasatinib. Given that *NF1* loss leads to RAS pathway activation it is likely that its loss has the potential to drive resistance to tyrosine kinase inhibitors in a variety of settings given the central role of RAS signaling in cancer. While knockdown of ERK1/2 was sufficient to kill NCI-H2286 dasatinib resistant cells in our assays there remains a need to develop improved inhibitors of RAS pathway effectors given the central role of this pathway in cancer development, progression and therapeutic resistance. It is interesting to note that we observed a dominant effect of ERK and not MEK downstream of *NF1* loss in our dasatinib resistant cell lines. While the mechanism of this observation remains unclear a recent study has reported a similar observation in melanoma cell lines rendered resistant to the RAF inhibitor vemurafenib (52). It may be the case that MEK is subject to feedback inhibition in the setting of ERK activation downstream of *NF1* loss or a parallel MEK independent pathway could be driving ERK activation.

Our data are unlikely to represent a full accounting of mechanisms of acquired resistance to dasatinib in lung cancer and it is also likely that some patients with *DDR2* mutations in ongoing clinical trials will display primary resistance to dasatinib given that many *DDR2* mutations have been described and some of these may not confer sensitivity to dasatinib. As we only profiled 645 genes in our sequencing assay and since knock-down of *NF1* did not fully recapitulate the degree of dasatinib resistance observed in NCI-H2286-DR, we expect that additional mechanisms will likely be found as has been the case for acquired resistance to *EGFR* and *BRAF* directed therapies. Further, it is possible that more than one mechanism may drive resistance in a particular context and that some mechanisms may involve alterations other than DNA mutations such as changes in gene expression or the epigenetic state of the cell. It remains to be seen what the diversity of mechanisms of acquired resistance to dasatinib will be. Given the ongoing clinical trials of dasatinib in genotypically selected patients with non-small cell lung cancer, we think that the establishment of additional models of resistance including serial biopsies of patients who respond to

treatment on study, will be critical to allow for the best design of strategies to overcome acquired resistance to dasatinib.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Financial Support: This work was supported by Young Investigator Awards from the National Lung Cancer Partnership and American Society of Clinical Oncology to P.S. Hammerman, NCI K08 CA163677 to P.S. Hammerman, the Stephen D. and Alice Cutler Fund to P.S. Hammerman, and NCI P01 CA154303 to M. Meyerson.

References

1. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science*. 2004; 304:1497–1500. [PubMed: 15118125]
2. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med*. 2004; 350:2129–2139. [PubMed: 15118073]
3. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proc Natl Acad Sci U S A*. 2004; 101:13306–13311. [PubMed: 15329413]
4. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature*. 2007; 448:561–566. [PubMed: 17625570]
5. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. *Lancet Oncol*. 2011; 12:1004–1012. [PubMed: 21933749]
6. Naoki K, Chen TH, Richards WG, Sugarbaker DJ, Meyerson M. Missense mutations of the BRAF gene in human lung adenocarcinoma. *Cancer Res*. 2002; 62:7001–7003. [PubMed: 12460919]
7. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. Somatic mutations affect key pathways in lung adenocarcinoma. *Nature*. 2008; 455:1069–1075. [PubMed: 18948947]
8. Bergethson K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, et al. ROS1 rearrangements define a unique molecular class of lung cancers. *J Clin Oncol*. 2012; 30:863–870. [PubMed: 22215748]
9. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. *Cell*. 2007; 131:1190–1203. [PubMed: 18083107]
10. Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, Jarosz M, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. *Nat Med*. 2012; 18:382–384. [PubMed: 22327622]
11. Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T, et al. KIF5B-RET fusions in lung adenocarcinoma. *Nat Med*. 2012; 18:375–377. [PubMed: 22327624]
12. Ju YS, Lee WC, Shin JY, Lee S, Bleazard T, Won JK, et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. *Genome Res*. 2012; 11:2109–2119. [PubMed: 22975805]
13. WHO [internet]. Geneva: World Health Organization; c2013 [updated 2013 Jan; cited 2013 Oct 1]. Available from: <http://www.who.int/mediacentre/factsheets/fs297/en/>.
14. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. *Sci Transl Med*. 2010; 2 62ra93.

15. Dutt A, Ramos AH, Hammerman PS, Mermel C, Cho J, Sharifnia T, et al. Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer. *PLoS One*. 2011; 6:e20351. [PubMed: 21666749]
16. Liao RG, Jung J, Tchaicha J, Wilkerson MD, Sivachenko A, Liu Q, et al. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. *Cancer Res*. 2013; 16:5195–5205. [PubMed: 23786770]
17. Majewski IJ, Mittempergher L, Davidson NM, Bosma A, Willems SM, Horlings HM, et al. Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centered RNA sequencing. *J Pathol*. 2013; 3:270–276. [PubMed: 23661334]
18. Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, et al. Identification of Targetable FGFR Gene Fusions in Diverse Cancers. *Cancer Discov*. 2013; 6:636–647. [PubMed: 23558953]
19. Hammerman PS, Sos ML, Ramos A, Xu C, Dutt A, et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. *Cancer Discovery*. 2011; 1:78–89. [PubMed: 22328973]
20. TCGA Network. Comprehensive genomic characterization of squamous cell lung cancers. *Nature*. 2012; 7417:519–525.
21. Wolf J, LoRusso PM, Camidge RD, Perez JM, Taberno J, Hidalgo M, et al. A phase I dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors. *Cancer Research*. 2012; 72(8 supplement) [abstract]. LB-122.
22. Pitini V, Arrigo C, Di Mirto C, Mondello P, Altavilla G. Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia. *Lung Cancer*. 2013; 1:171–172. [PubMed: 23932362]
23. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. *N Engl J Med*. 2005; 352:786–792. [PubMed: 15728811]
24. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. *PLoS Med*. 2005; 2:e73. [PubMed: 15737014]
25. Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. *Sci Transl Med*. 2012; 4:120ra17.
26. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. *N Engl J Med*. 2010; 363:1734–1739. [PubMed: 20979473]
27. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. *Science*. 2007; 316:1039–1043. [PubMed: 17463250]
28. Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, de Stanchina E, et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFR T790M mutation. *Cancer Discov*. 2012; 2:922–933. [PubMed: 22956644]
29. Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, Rogers A, et al. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. *Oncogene*. 2010; 29:2346–2356. [PubMed: 20118985]
30. Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K, et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. *Cancer Cell*. 2006; 9:485–495. [PubMed: 16730237]
31. Qi J, McTigue MA, Rogers A, Lifshits E, Christensen JG, Janne PA, et al. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. *Cancer Res*. 2011; 71:1081–1091. [PubMed: 21266357]
32. Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, Zheng W, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. *Cancer Res*. 2011; 71:6051–6060. [PubMed: 21791641]

33. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. *Cancer Cell*. 2010; 17:77–88. [PubMed: 20129249]
34. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. *Nature*. 2010; 468:968–972. [PubMed: 21107320]
35. Maertens O, Johnson B, Hollstein P, Frederick DT, Cooper ZA, Messiaen L, et al. Elucidating distinct roles for NF1 in melanomagenesis. *Cancer Discov*. 2013; 3:338–349. [PubMed: 23171796]
36. Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, et al. Phase I/II Study of the Src Inhibitor Dasatinib in Combination With Erlotinib in Advanced Non-Small-Cell Lung Cancer. *J Clin Oncol*. 2010; 28:1387–1394. [PubMed: 20142592]
37. Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran HT, et al. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. *J Clin Oncol*. 2010; 28:4609–4615. [PubMed: 20855820]
38. Johnson ML, Riely GJ, Rizvi NA, Azzoli CG, Kris MG, Sima CS, et al. Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib. *J Thorac Oncol*. 2011; 6:1128–1131. [PubMed: 21623279]
39. Sen B, Peng S, Tang X, Erickson HS, Galindo H, Mazumdar T, et al. Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib. *Sci Transl Med*. 2012; 4:136ra70.
40. Labrador JP, Azcoitia V, Tuckermann J, Lin C, Olaso E, Manes S, et al. The collagen receptor DDR2 regulates proliferation and its elimination leads to dwarfism. *EMBO Rep*. 2001; 2:446–452. [PubMed: 11375938]
41. Leiting B. Molecular analysis of collagen binding by the human discoidin domain receptors, DDR1 and DDR2. Identification of collagen binding sites in DDR2. *J Biol Chem*. 2003; 278:16761–16769. [PubMed: 12611880]
42. Curat CA, Vogel WF. Discoidin domain receptor 1 controls growth and adhesion of mesangial cells. *J Am Soc Nephrol*. 2002; 13:2648–2656. [PubMed: 12397034]
43. Ikeda K, Wang LH, Torres R, Zhao H, Olaso E, Eng FJ, et al. Discoidin domain receptor 2 interacts with Src and Shc following its activation by type I collagen. *J Biol Chem*. 2002; 277:19206–19212. [PubMed: 11884411]
44. Olaso E, Labrador JP, Wang L, Ikeda K, Eng FJ, Klein R, et al. Discoidin domain receptor 2 regulates fibroblast proliferation and migration through the extracellular matrix in association with transcriptional activation of matrix metalloproteinase-2. *J Biol Chem*. 2002; 277:3606–3613. [PubMed: 11723120]
45. Vogel W, Brakebusch C, Fassler R, Alves F, Ruggiero F, Pawson T. Discoidin domain receptor 1 is activated independently of beta(1) integrin. *J Biol Chem*. 2000; 275:5779–5784. [PubMed: 10681566]
46. Vogel WF, Aszodi A, Alves F, Pawson T. Discoidin domain receptor 1 tyrosine kinase has an essential role in mammary gland development. *Mol Cell Biol*. 2001; 21:2906–2917. [PubMed: 11283268]
47. Yang K, Kim JH, Kim HJ, Park IS, Kim IY, Yang BS. Tyrosine 740 phosphorylation of discoidin domain receptor 2 by Src stimulates intramolecular autophosphorylation and Shc signaling complex formation. *J Biol Chem*. 2005; 280:39058–39066. [PubMed: 16186108]
48. Day E, Waters B, Spiegel K, Alnadaf T, Manley PW, Buchdunger E, et al. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. *Eur J Pharmacol*. 2008; 599:44–53. [PubMed: 18938156]
49. Wagle N, Berger MF, Davis MJ, Blumenstiel B, Defelice M, Pochanard P, et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. *Cancer Discov*. 2012; 2:82–93. [PubMed: 22585170]
50. Du J, Bernasconi P, Clauser KR, Mani DR, Finn SP, Beroukhi R, et al. Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. *Nat Biotechnol*. 2009; 27:77–83. [PubMed: 19098899]

51. Oricchio E, Wendel HG. Mining the cancer genome uncovers therapeutic activity of EphA7 against lymphoma. *Cell Cycle*. 2012; 11:1076–1080. [PubMed: 22356769]
52. Whittaker SR, Theurillat JP, Van Allen E, Wagle N, Hsiao J, Cowley GS, et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. *Cancer Discov*. 2013; 3:350–362. [PubMed: 23288408]
53. Ramos AH, Dutt A, Mermel C, Perner S, Cho J, Lafargue CJ, et al. Amplification of chromosomal segment 4q12 in non-small cell lung cancer. *Cancer Biol Ther*. 2009; 8:2042–2050. [PubMed: 19755855]
54. Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M, et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. *Nature*. 2009; 462:1070–1074. [PubMed: 20033049]

A

B

Figure 1.

Dasatinib resistant lines generated from *DDR2*-dependent lung cancer cell lines exhibit decreased sensitivity to dasatinib and have acquired alterations not present in the parental cell lines. **A**, Proliferation of NCI-H2286, HCC-366 and generated dasatinib resistant lines NCI-H2286-DR and HCC-366-DR grown for 6 days in the presence of dasatinib. Calculated GI₅₀s for each line are shown in the table. **B**, Immunoblot showing levels of *DDR2* in NCI-H2286 and HCC-366 parental and dasatinib resistant lines.

Figure 2.

NCI-H2286 cells treated with RNAi targeting *NF1* have decreased *NF1* mRNA and protein levels and decreased sensitivity to dasatinib. **A**, Immunoblot showing NF1 protein levels in NCI-H2286, NCI-H2286-DR, and NCI-H2286 cells expressing shRNA vectors targeting *NF1* (shNF1a-e), *GFP* (shGFP), or *lacZ* (shLacZ29). **B**, Relative levels of *NF1* mRNA in NCI-H2286 cells expressing shRNA vectors to knock-down *GFP* (shGFP) or *NF1* (shNF1a-e), measured by real-time PCR. **C**, Proliferation of NCI-H2286, NCI-H2286-DR, and NCI-H2286 cells expressing shRNA vectors targeting *lacZ* or *NF1*, grown for 6 days in the presence of dasatinib. Calculated GI₅₀s are shown in the table.

Figure 3. p-ERK levels are maintained in dasatinib resistant, but not parental, NCI-H2286 following dasatinib treatment. Immunoblots showing relative levels of the proteins ERK, Src, MEK, and AKT and phosphoproteins p-ERK (Thr202/Tyr204), p-Src (Tyr416), p-MEK (Ser217/221), and p-AKT (Ser473) in NCI-H2286 and NCI-H2286-DR treated with various concentrations of dasatinib.

Figure 4. NCI-H2286-DR demonstrates increased RAS activity compared to parental NCI-H2286 and demonstrates ERK dependence. **A**, Immunoblot showing RAS-GTP in NCI-H2286 and NCI-H2286-DR, measured by RAS GTP pull-down and bar graph showing RAS GTPase activity. **B**, Cell viability of NCI-H2286 and NCI-H2286-DR 24, 48 and 72 hours after addition of siRNA targeting *ERK1/2*. The immunoblot shows the decrease in ERK protein levels in NCI-H2286 and NCI-H2286-DR upon knock-down of *ERK1/2* by RNAi.

A

B

Figure 5.

Knock-down of *NF1* in two additional dasatinib-sensitive cell lines leads to a decrease in dasatinib sensitivity. **A**, NF1 protein levels in NCI-H1703 and HCC-366 cells expressing an shRNA vector targeting *NF1* (shNF1b) are shown relative to parental NCI-H1703 and HCC-366 lines in the immunoblot. **B**, Proliferation of NCI-H1703 and HCC-366 cells expressing an shRNA vector targeting either *NF1* or *GFP* was measured after 6 days in the presence of dasatinib. Calculated GI₅₀s are shown in the table.

Table 1

List of nucleotide variants present in the dasatinib resistant lines and not in the parental lines, identified by targeted exome sequencing.

Cell Line	Nucleotide Variant	Amino Acid Change
HCC-366-DR-1	DDR2 1961C>T	DDR2 T654I
HCC-366-DR-2	None	
NCI-H2286-DR-1	NF1 1392 splice G>A	NF1 P464 splice (exon 12)
NCI-H2286-DR-1	EPHA7 1678G>T	EPHA7 V560L
NCI-H2286-DR-2	IL6ST 1990G>T	IL6ST A664S